A client with chronic hepatitis D is prescribed antiviral therapy. What statement by the client demonstrates understanding of the treatment regimen?

Choice A rationale:

The client's statement, "I will take pegylated interferon-alpha as the antiviral agent," demonstrates understanding of the treatment regimen for chronic hepatitis

D. Pegylated interferon-alpha is the recommended antiviral therapy for chronic hepatitis

D. It helps suppress viral replication and reduce liver inflammation, which is essential in managing the disease. Interferon therapy can be used alone or in combination with antiviral agents like lamivudine or adefovir. However, it is crucial to note that interferon therapy may have side effects, and the client should be educated about them.

Choice B rationale:

"I will use ribavirin to suppress viral replication" is incorrect. Ribavirin is an antiviral agent used for the treatment of hepatitis C but is not typically recommended for hepatitis

D. The primary antiviral therapy for hepatitis D is pegylated interferon-alpha.

Choice C rationale:

"I need to continue the treatment for a shorter duration than hepatitis B or C" is incorrect. The treatment duration for chronic hepatitis D is generally longer than that for hepatitis B or

C. The therapy may last for six months to a year or even longer, depending on the individual response to treatment and the level of liver damage.

Choice D rationale:

"The goal of treatment is to achieve undetectable HDV RNA after the treatment ends" is incorrect. While achieving undetectable HDV RNA is a favorable outcome, it may not always be achievable with current therapies. The primary goal of treatment is to suppress viral replication, reduce liver inflammation, and slow down the progression of liver disease.

Choice A rationale:

Fulminant hepatitis is a severe and life-threatening complication of hepatitis E, particularly in pregnant women. It can lead to liver failure, and timely monitoring is crucial to detect any early signs of deterioration in the patient's condition. Pregnant women with hepatitis E require close observation and frequent assessment of liver function to ensure prompt intervention if needed.

Choice B rationale:

Administering hepatitis B immunoglobulin (HBIG) to exposed contacts is not the priority in managing a patient with hepatitis

E. Hepatitis E is caused by a different virus (hepatitis E virus) and is not effectively prevented by hepatitis B immunoglobulin.

Choice C rationale:

Educating the patient about the benefits of hepatitis C vaccine is not relevant to the care of a patient with hepatitis

E. These are two different types of viral hepatitis, caused by distinct viruses (hepatitis C virus and hepatitis E virus), and each requires specific management.

Choice D rationale:

Advising the patient to avoid sexual contact until cleared of infection is important in some cases, but it is not the priority intervention for a patient with hepatitis

E. The primary concern in hepatitis E is monitoring for complications, especially in pregnant women, as discussed in choice A rationale.